- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | MAIA Biotechnology, Inc.: MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum | 229 | GlobeNewswire (Europe) | High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA's Fast Track designation for ateganosine... ► Artikel lesen | |
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 13.01. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings | 256 | GlobeNewswire (Europe) | Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA)... ► Artikel lesen | |
| 16.12.25 | MAIA Biotechnology announces $1.51M private placement | 2 | Seeking Alpha | ||
| 16.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces $1.51 Million Private Placement | 3 | GlobeNewswire (USA) | ||
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates | 141 | GlobeNewswire (Europe) | CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA),... ► Artikel lesen | |
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer | 338 | GlobeNewswire (Europe) | Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE... ► Artikel lesen | |
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential | 4 | GlobeNewswire (USA) | ||
| 10.12.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.12.25 | MAIA Biotechnology, Inc.: MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach | 108 | GlobeNewswire (Europe) | CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) - The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade... ► Artikel lesen | |
| 01.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases by CEO and Directors | 1 | GlobeNewswire (USA) | ||
| 21.11.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 | 288 | GlobeNewswire (Europe) | Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO, Nov. 21, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 20.11.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.11.25 | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Maia Biotechnology stellt Studiendaten auf der SITC-Konferenz 2025 vor | 1 | Investing.com Deutsch | ||
| 07.11.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.10.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.10.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | 237 | GlobeNewswire (Europe) | Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the... ► Artikel lesen | |
| 14.10.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 106,00 | +0,06 % | GILEAD SCIENCES INC CDR - Ruhe als strategisches Signal | ||
| ABBVIE | 183,20 | +0,33 % | Dividendenbekanntmachungen (16.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBVIE INC US00287Y1091 1,73 USD 1,4902 EUR ABBVIE INC CDR CA00288K1084 0,2439 CAD 0,1512 EUR ALAMO GROUP INC US0113111076 0... ► Artikel lesen | |
| ABBOTT LABORATORIES | 103,50 | +0,14 % | Dividendenbekanntmachungen (15.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AB DYNAMICS PLC GB00B9GQVG73 0,0636 GBP 0,0734 EUR ABBOTT LABORATORIES US0028241000 0,63 USD 0,541 EUR ABBOTT LABORATORIES CDR CA0028221046 0... ► Artikel lesen | |
| SCHOTT PHARMA | 14,260 | 0,00 % | ANALYSE-FLASH: Jefferies senkt Ziel für Schott Pharma auf 15,50 Euro - 'Hold' | NEW YORK (dpa-AFX Broker) - Das Analysehaus Jefferies hat das Kursziel für Schott Pharma von 24,70 auf 15,50 Euro gesenkt, aber die Einstufung auf "Hold" belassen. 2026 werde ein Übergangsjahr für... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 71,24 | +0,06 % | Does Edwards Lifesciences (EW) Have Strong Double-Digit Earnings Potential? | ||
| ASSEMBLY BIOSCIENCES | 23,000 | +0,44 % | Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs | FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase... ► Artikel lesen | |
| PENTIXAPHARM | 2,085 | +3,73 % | Pentixapharm: FDA hat "keine wesentlichen Bedenken" zur Phase-3-Studie mit PentixaFor | Die Pentixapharm Holding AG hat von der U.S. Food and Drug Administration das formelle schriftliche Protokoll eines Meetings zur geplanten Phase-3-PANDA-Studie erhalten. Nach Angaben des Unternehmens... ► Artikel lesen | |
| CASSAVA SCIENCES | 1,712 | +0,56 % | Cassava Sciences, Inc.: Cassava Announces Agreement to Settle Securities Class Action Litigation | AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 158,70 | +0,83 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia | NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today... ► Artikel lesen | |
| MEDPACE | 515,40 | +0,27 % | Medpace Holdings - MEDP: Kapitalrendite besser als bei Iqvia, Thermo Fisher & Icon! | Kursziel 700 USD! Erwartungen übertroffen, Prognose angehoben! Medpace-Aktie (MEDP) mit Gap Ups nach den letzten beiden Quartalszahlen! Medpace (MEDP) - ISIN US58506Q1094 Rückblick: Ein Kursplus von... ► Artikel lesen | |
| ZEALAND PHARMA | 53,84 | +0,04 % | Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy | Press release - No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark's... ► Artikel lesen | |
| UNITED THERAPEUTICS | 395,30 | 0,00 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| UCB | 254,60 | -0,24 % | Lee's Pharmaceutical Holdings Limited: Lee's Pharmaceutical Holdings Limited Acquires Staccato One Breath Technology Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights | Acquisition of Staccato One Breath Technology, a proprietary platform technology with broad therapeutic potentialSynergistic and complementary to Lee's Pharm's existing products pipeline... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 415,70 | -3,55 % | 10 Analysts Have This To Say About Madrigal Pharmaceuticals | ||
| BRIDGEBIO PHARMA | 65,78 | -0,12 % | BridgeBio Pharma, Inc.: BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 | The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturityOffering priced at 0.75% interest rate and 45% conversion premium PALO ALTO... ► Artikel lesen |
MAIA BIOTECHNOLOGY INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.